DOCSLIB.ORG

Matrixx Initiatives, Inc. (Exact Name of Registrant As Specified in Its Charter) Delaware 87-0482806 (State Or Other Jurisdiction (I.R.S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Matrixx Initiatives, Inc. (Exact Name of Registrant As Specified in Its Charter) Delaware 87-0482806 (State Or Other Jurisdiction (I.R.S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ¥ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2009 or n FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-31404 Matrixx Initiatives, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 87-0482806 (State or Other Jurisdiction (I.R.S. Employer of Incorporation or Organization) Identification No.) 8515 E. Anderson Drive Scottsdale, AZ 85255 602-385-8888 (Address of principal executive offices, Registrant’s Telephone Number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $.001 par value Nasdaq Global Select Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes n No ¥ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes n No ¥ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ¥ No n Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes n No n Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K, is not to be contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¥ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer n Accelerated filer ¥ Non-accelerated filer n Smaller reporting company n (Do not check if a smaller reporting company) Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes n No ¥ The aggregate market value of the voting stock held by non-affiliates of the registrant was approximately $116.8 million based on the closing price of $17.88 per share of common stock as reported on the Nasdaq Global Select Market on September 30, 2008. For purposes of this determination, shares of common stock held by each officer and director and by each person who owns 5% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes. As of June 1, 2009, 9,430,320 shares of the registrant’s common stock were outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s definitive proxy statement prepared in connection with the Registrant’s 2009 annual meeting of stockholders are incorporated by reference into Part III, Items 10, 11, 12, 13 and 14 of this Form 10-K. Unless otherwise indicated in this Form 10-K, “Matrixx,” “us,” “we,” “our,” “the Company” and similar terms refer to Matrixx Initiatives, Inc. and its subsidiaries. “Zicam” is a registered trademark of our subsidiary, Zicam, LLC, and the Matrixx name and logo are trademarks of the Company. 2 TABLE OF CONTENTS Page PART I Item 1. Business ............................................................... 4 Item 1A. Risk Factors ............................................................ 10 Item 1B. Unresolved Staff Comments ................................................. 16 Item 2. Properties .............................................................. 16 Item 3. Legal Proceedings ........................................................ 16 Item 4. Submission of Matters to a Vote of Security Holders .............................. 21 Supplemental Item. Executive Officers of Matrixx ................................ 21 PART II Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities ............................................... 22 Item 6. Selected Financial Data .................................................... 25 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations . 25 Item 7A. Quantitative and Qualitative Disclosures about Market Risk ......................... 42 Item 8. Financial Statements and Supplementary Data . ................................. 43 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure . 43 Item 9A. Controls and Procedures ................................................... 43 Item 9B. Other Information ........................................................ 45 PART III Item 10. Directors, Executive Officers, and Corporate Governance ........................... 45 Item 11. Executive Compensation ................................................... 45 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters ................................................................ 45 Item 13. Certain Relationships and Related Transactions, and Director Independence ............. 46 Item 14. Principal Accounting Fees and Services ........................................ 46 PART IV Item 15. Exhibits and Financial Statement Schedules ..................................... 47 SIGNATURES ................................................................... 74 3 PART I ITEM 1. BUSINESS Introduction We develop, produce, market and sell innovative, over-the-counter (OTC) healthcare products with an emphasis on those that utilize unique, novel and/or proprietary delivery systems that provide consumers with “Better Ways to Get Better».” Through our subsidiaries, we market and sell products under the Zicam» brand. As discussed in more detail below, our current Zicam offerings compete in the following four product classes within the cough and cold category: Cold Remedy; Allergy/Sinus; Cough and Multi-Symptom relief; and other cough/cold. In addition, we have sold products under the Nasal Comfort» and Xcid» brand names. We were incorporated in Utah in 1991 as Gum Tech International, Inc. On June 18, 2002, we reincorporated in Delaware and changed our name from Gum Tech International, Inc. to Matrixx Initiatives, Inc. We generally conduct our business through our wholly-owned subsidiaries. We develop and market our Zicam products through Zicam, LLC. In May 2008, we formed Zicam Canada, Inc. to commercialize sales of Zicam products in Canada. We have sales in one business segment, over-the-counter healthcare products. Currently, substantially all of our revenues are attributed to sales within the United States; we had initial international sales in Canada in fiscal 2009 of approximately $1.0 million. Our net sales were approximately $111.6 million for the fiscal year ended March 31, 2009, compared to net sales for the fiscal year ended March 31, 2008 of approximately $101.0 million. Our net income was $13.9 million for the fiscal year ended March 31, 2009, and $10.4 million for the fiscal year ended March 31, 2008. As used herein, except as otherwise indicated, references to “we,” “us,” “our,” or the “Company” refer to Matrixx Initiatives, Inc. and its subsidiaries. Access to Our Filings with the Securities and Exchange Commission Our website is www.matrixxinc.com. Through a link on the Financial Information section of our website, we make available the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the SEC: our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934. All such filings are available free of charge. Information contained on the Company’s website is not part of this report. Our principal executive offices are at 8515 E. Anderson Drive, Scottsdale, AZ 85255 and our telephone number is (602) 385-8888. Markets and Company Products Our current Zicam products are marketed in the cough and cold market category. That market, which is estimated at more than $4.0 billion annually in retail sales in the United States, includes a wide variety of tablets, liquids, gels, sprays, and syrups that remedy and/or provide relief to cold, allergy and sinus congestion sufferers. The largest sub-segment of the cough and cold category includes products formulated to relieve symptoms associated with the common cold or allergies. 4 In February 2007, the Company changed its fiscal year-end from December 31 to March 31. The following table details our sales
Load more

Recommended publications
  • Section 4: Business Institute of Bill of Rights Law at the William & Mary Law School
    College of William & Mary Law School William & Mary Law School Scholarship Repository Supreme Court Preview Conferences, Events, and Lectures 2010 Section 4: Business Institute of Bill of Rights Law at the William & Mary Law School Repository Citation Institute of Bill of Rights Law at the William & Mary Law School, "Section 4: Business" (2010). Supreme Court Preview. 198. https://scholarship.law.wm.edu/preview/198 Copyright c 2010 by the authors. This article is brought to you by the William & Mary Law School Scholarship Repository. https://scholarship.law.wm.edu/preview IV. Business In This Section: New Case: 09-152 Bruesewitz v. Wyeth, Inc. p. 107 Synopsis and Questions Presented p. 107 "SUPREME COURT ACCEPTS APPEAL OVER VACCINE SAFETY" p. 120 Bill Mears "3RD CIRCUIT: KIDS HURT BY VACCINES CAN'T PURSUE DESIGN DEFECT p. 122 CLAIMS" Shannon P. Duffy "VACCINE COURT FINDS No LINK TO AUTISM" p. 125 CN.com "SUIT SAYS MT. LEBANON GIRL SUFFERED SEVERE BRAIN DAMAGE" p. 128 Brian Bowling New Case: 09-329 Chase Bank USA, N.A. V. McCoy p. 130 Synopsis and Questions Presented p. 130 "SUPREME COURT TO HEAR JPMORGAN APPEAL IN CARD CASE" p. 141 James Vicini 7TH CIRCUIT RULES BANK CAN RAISE INTEREST RATE WITHOUT NOTICE p. 142 David Ziemer "BANK OF AMERICA WINS CREDIT CARD FEE LAWSUIT" p. 145 Jonathan Stempel "CREDIT CARD COMPANIES ADD TO ECONOMIC WOES" p. 146 Jann Swanson "CONSUMERS ARE DEALT A NEW HAND IN CREDIT CARDS" p. 148 Ron Lieber New Case: 08-1423 Costco Wholesale Corp. v. Omega, S.A. p. 150 Synopsis and Questions Presented p.
    [Show full text]
  • Zinc Toxicity in Odora Cells
    Zinc Toxicity in Odora Cells A thesis submitted to the University of Cincinnati Division of Graduate Studies in partial fulfillment of the requirements for the degree of Master of Science in the Department of Environmental Health of the College of Medicine by Heidi Hsieh A.B. Harvard University August 2011 Committee: Mary Beth Genter, Ph.D. (Chair) Hassane Amlal, Ph.D. Abstract Zinc has been touted as a panacea for the common cold. However, there has been some controversy over whether Zicam, an intranasal zinc gluconate gel purported to fight colds, causes anosmia, or the loss of the sense of smell. Historical evidence has shown that zinc sulfate solutions can cause anosmia in humans along with significant damage to the olfactory epithelium in rodents. However, more recent work has claimed to show that zinc gluconate is less toxic than zinc sulfate. Using an in vitro system to compare the toxicity of zinc sulfate and zinc gluconate on immature and mature rat olfactory sensory neurons, it was found that the toxicity of both zinc salts was similar with zinc sulfate being slightly more toxic than zinc gluconate and occurred at significantly lower concentrations than that found in Zicam nasal gel, which strengthens the epidemiological link between intranasal zinc exposure and anosmia. Mechanistic studies disproved the hypothesis that zinc toxicity was caused by inhibition of the HVCN1 proton channel which would have led to acidosis and apoptotic cell death. It was found that these immature rat olfactory sensory neurons are able to maintain their intracellular pH through a + + - - Na /H exchanger, specifically NHE1, and a Cl /HCO3 exchanger.
    [Show full text]
  • United States District Court Southern District of New York
    Case 7:15-cv-09843 Document 1 Filed 12/17/15 Page 1 of 32 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ALAN GULKIS, individually and on behalf of all others similarly situated, Plaintiff, CLASS ACTION COMPLAINT v. ZICAM LLC and MATRIXX INITIATIVES, JURY TRIAL DEMANDED INC. Defendants. Plaintiff Alan Gulkis (“Plaintiff”), by his attorneys, makes the following allegations pursuant to the investigation of his counsel and based upon information and belief, except as to allegations specifically pertaining to himself and his counsel, which are based on personal knowledge. NATURE OF ACTION 1. Defendants Zicam LLC and Matrixx Initiatives, Inc. (collectively “Defendants”) sell fake medicine to consumers seeking treatment for cold symptoms. Double-blind placebo- controlled trials show that Defendants’ “Zicam Pre-Cold Medicine” is nothing more than a placebo. Even though Defendants know that studies show that the “Pre-Cold Medicine” is no different than a placebo, Defendants represent that the “Pre-Cold Medicine” shortens and reduces the severity of cold symptoms, and that the “Pre-Cold Medicine” prevents full cold symptoms from occurring. Defendants have made millions of dollars selling dummy pills to New York residents. 2. Because Defendants’ Pre-Cold Medicine Products are mere placebos, Defendants’ representations that their Products shorten and reduce the severity of the common cold, as well as their representations that the Products stop full cold symptoms are false and misleading. The 1 Case 7:15-cv-09843 Document 1 Filed 12/17/15 Page 2 of 32 Pre-Cold Medicine includes Zicam Pre-Cold RapidMelts Original, Zicam Pre-Cold RapidMelts Ultra, Zicam Pre-Cold Oral Mist, Zicam Pre-Cold Ultra Crystals, Zicam Pre-Cold Lozenges, Zicam Pre-Cold Lozenges Ultra, and Zicam Pre-Cold Chewables (“Pre-Cold Medicine,” “Pre- Cold Products,” or “Products”).
    [Show full text]
  • ZICAM® COLD REMEDY Drug Facts
    ZICAM COLD REMEDY- galphimia glauca flowering top, luffa operculata fruit, and schoenocaulon officinale seed spray Matrixx Initiatives, Inc. Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective. ---------- ZICAM® COLD REMEDY Drug Facts Active ingredients Galphimia glauca 4x, Luffa operculata 4x, Sabadilla 4x Purpose Reduces duration and severity of the common cold Uses reduces duration of the common cold reduces severity of cold symptoms: dry, scratchy throat runny nose watery eyes sneezing nasal congestion Zicam® Cold Remedy was formulated to shorten the duration of the common cold and may not be effective for flu or allergies. Warnings For nasal use only Do not use if you have a sensitivity or allergy to any of the ingredients. If an allergic reaction occurs, stop use and seek medical help right away. Ask a doctor before use if you have ear, nose, or throat sensitivity susceptibility to nosebleeds When using this product avoid contact with eyes. Rinse right away with water if it gets in eyes and seek medical help right away. the use of this container by more than one person may spread infection temporary discomfort such as burning, stinging, sneezing, or an increase in nasal discharge may occur Stop use and ask a doctor if symptoms get worse or last more than 7 days or are accompanied by fever redness or swelling is present new symptoms occur If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children.
    [Show full text]
  • Reconciling Their Interests in Regulating Homeopathic Products, 49 J
    UIC Law Review Volume 49 Issue 4 Article 7 Summer 2016 The Food and Drug Administration Versus the Federal Trade Commission: Reconciling Their Interests in Regulating Homeopathic Products, 49 J. Marshall L. Rev. 1193 (2016) Jordannah Bangi Follow this and additional works at: https://repository.law.uic.edu/lawreview Part of the Administrative Law Commons, Antitrust and Trade Regulation Commons, and the Food and Drug Law Commons Recommended Citation Jordannah Bangi, The Food and Drug Administration Versus the Federal Trade Commission: Reconciling Their Interests in Regulating Homeopathic Products, 49 J. Marshall L. Rev. 1193 (2016) https://repository.law.uic.edu/lawreview/vol49/iss4/7 This Comments is brought to you for free and open access by UIC Law Open Access Repository. It has been accepted for inclusion in UIC Law Review by an authorized administrator of UIC Law Open Access Repository. For more information, please contact [email protected]. THE FOOD AND DRUG ADMINISTRATION VERSUS THE FEDERAL TRADE COMMISSION: RECONCILING THEIR INTERESTS IN REGULATING HOMEOPATHIC PRODUCTS JORDANNAH BANGI* I. THE POPULARITY AND GROWING SAFETY CONCERNS FOR HOMEOPATHIC PRODUCTS SPUR FDA AND FTC SCRUTINY ... 1194 II. HOMEOPATHY AND THE CONFLICT BETWEEN THE FDA AND THE FTC’S POLICIES ON REGULATING HOMEOPATHIC PRODUCTS ......................................................................... 1197 A. The Principles and Practice of Homeopathy ................ 1197 1. Basic Principles of Homeopathy ............................ 1197 2. Types of Homeopathic
    [Show full text]
  • Zicam® Cold Remedy Oral Mist™ Drug Facts
    ZICAM COLD REMEDY ORAL MIST- zinc acetate and zinc gluconate spray Matrixx Initiatives, Inc. Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective. ---------- Zicam® Cold Remedy Oral Mist™ Drug Facts Active ingredients Zincum aceticum 2x Zincum gluconicum 1x Purpose Reduces duration and severity of the common cold Uses reduces duration of the common cold helps reduce severity of cold symptoms: sore throat stuffy nose sneezing coughing nasal congestion Zicam® Cold Remedy was formulated to shorten the duration of the common cold and was not formulated to be effective for flu or allergies. Warnings For oral use only Sore throat warning If sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, nausea, or vomiting, consult a doctor promptly. Ask a doctor before use if you have a sensitivity to zinc or are allergic to zinc When using this product avoid contact with eyes. Rinse right away with water if it gets in eyes and seek medical help right away. Stop use and ask a doctor if symptoms, including cough, persist, recur or are accompanied by a fever, rash, or persistent headache, or if new symptoms occur. A persistent cough that lasts for more than one week may be a sign of a serious condition. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
    [Show full text]
  • Siracusano V. Matrixx Initiatives
    FOR PUBLICATION UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT JAMES SIRACUSANO, Individually and on behalf of all others similarly situated, Plaintiff-Appellant, No. 06-15677 NECA-IBEW PENSION FUND, D.C. Nos. Claimant-Appellant, CV 04-0886 MHM CV 04-1012 MHM v. OPINION MATRIXX INITIATIVES, INC.; CARL J. JOHNSON; WILLIAM J. HEMELT, Defendants-Appellees. Appeal from the United States District Court for the District of Arizona Mary H. Murguia, District Judge, Presiding Argued and Submitted June 9, 2009—San Francisco, California Filed October 28, 2009 Before: Mary M. Schroeder, A. Wallace Tashima and Carlos T. Bea, Circuit Judges. Opinion by Judge Tashima 14507 14510 SIRACUSANO v. NECA-IBEW PENSION FUND COUNSEL Joseph D. Daley, Coughlin Stoia Geller Rudman & Robbins LLP, San Diego, California, for the plaintiff-appellant. Michael G. Yoder, O’Melveny & Myers LLP, Newport Beach, California, for the defendants-appellees. SIRACUSANO v. NECA-IBEW PENSION FUND 14511 OPINION TASHIMA, Circuit Judge: Matrixx Initiatives, Inc. (“Matrixx”) is a pharmaceutical company that sells cold products through its wholly-owned subsidiary, Zicam, LLC. One of its main products is Zicam Cold Remedy, which comes in several different forms.1 Plaintiffs-Appellants are lead plaintiff, NECA-IBEW Pension Fund, and named plaintiff, James Siracusano, in a class action brought against Matrixx and three Matrixx executives (collec- tively “Appellees”) under the Private Securities Litigation Reform Act of 1995 (“PSLRA”). Appellants alleged that Appellees violated the Securities Exchange Act of 1934 by failing to disclose material information regarding Zicam Cold Remedy — specifically, that Zicam causes a condition called anosmia, which is a loss of the sense of smell, in its users.
    [Show full text]
  • Zicam ® Cold Remedy Zinc and Elderberry Lozenge
    ZICAM COLD REMEDY ZINC AND ELDERBERRY LOZENGE- zinc acetate anhydrous, zinc gluconate, and sambucus nigra flowering top lozenge Church & Dwight Co., Inc. Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective. ---------- Zicam ® Cold Remedy Zinc and Elderberry Lozenge Active ingredients (in each lozenge) Zincum aceticum 2x Zincum gluconicum 2x Sambucus nigra (elderberry) 4x Purpose Active ingredients (in each Purpose tablet) Zincum aceticum 2x Reduces duration of the common cold and helps relieve nasal congestion Zincum gluconicum 2x Sambucus nigra (elderberry) Helps relieve cold 4x symptoms * * Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated. Uses Reduces duration of the common cold and helps relieve nasal congestion ------------------------------------------------------------------------------------------------------ Zicam ® Cold Remedy was not formulated to be effective for flu and allergies. Warnings Sore throat warning: If sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, nausea, or vomiting, consult a doctor promptly. If you are allergic or sensitive to zinc, consult a doctor before using. Stop use and ask a doctor if symptoms, including cough, persist, recur or are accompanied by a fever, rash, or persistent headache, or if new symptoms occur. A persistent cough that lasts for more than one week may be a sign of a serious condition. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
    [Show full text]
  • Zicam® Cold Remedy Medicated Fruit Drops Drug Facts
    ZICAM COLD REMEDY MEDICATED FRUIT DROPS- zinc acetate anhydrous and zinc gluconate bar, chewable Matrixx Initiatives, Inc. Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective. ---------- Zicam® Cold Remedy Medicated Fruit Drops Drug Facts Active ingredients (in each medicated drop) Zincum aceticum 2x Zincum gluconicum 2x Purpose Reduces duration and severity of the common cold Uses reduces duration of the common cold helps reduce severity of cold symptoms: sore throat stuffy nose sneezing coughing nasal congestion Zicam® Cold Remedy was formulated to shorten the duration of the common cold and was not formulated to be effective for flu or allergies. Warnings Ask a doctor before use if you have a sensitivity to zinc or are allergic to zinc Stop use and ask a doctor if symptoms persist or are accompanied by a fever or new symptoms occur If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Directions for best results, use at the first sign of a cold and continue to use until symptoms completely subside adults and children 12 years of age and older: take one medicated drop at onset of symptoms chew slowly and dissolve completely before swallowing repeat every 2 – 3 hours, not to exceed 5 medicated drops in 24 hours. Take until symptoms are gone. to avoid minor stomach upset, do not take on an empty stomach do not eat or drink for 15 minutes after use.
    [Show full text]
  • Timothy Hall, Et Al. V. Hemelt, Et Al. 09-CV-01899-Verified Shareholder
    Case 2:09-cv-01899-SRB Document 1 Filed 09/11/09 Page 1 of 19 1 Eric L. Zagar Robin Winchester 2 BARROWAY TOPAZ KESSLER MELTZER & CHECK, LLP 3 280 King of Prussia Road 4 Radnor, PA 19087 Telephone: (610) 667-7706 5 Fax: (610) 667-7056 [email protected] 6 [email protected] 7 Robert D. Mitchell, 011922 Julie M. Beauregard, 023093 Sarah K. Deutsch, 026229 8 MITCHELL & ASSOCIATES 9 A Professional Corporation Viad Corporate Center, Suite 1715 1850 North Central Avenue 10 Phoenix, Arizona 85004 Telephone (602) 468-1411 11 Fax (602) 468-1311 [email protected] 12 [email protected] [email protected] 13 www.mitchell-attorneys.com 14 Counsel for Plaintiff 15 UNITED STATES DISTRICT COURT 16 DISTRICT OF ARIZONA 17 TIMOTHY HALL, Derivatively on Behalf of ) 18 Nominal Defendant MATRIXX INITIATIVES, ) INC., ) 19 Plaintiff, ) Case No. 20 v. ) ) 21 WILLIAM J. HEMELT, SAMUEL C. ) COWLEY, CARL J. JOHNSON, L. WHITE) VERIFIED SHAREHOLDER 22 MATTHEWS, III, MICHAEL A. ZEHER,) DERIVATIVE COMPLAINT 23 WILLIAM C. EGAN, LORI H. BUSH, and ) JOHN M. CLAYTON, ) 24 Defendants, ) 25 ) and ) JURY TRIAL DEMANDED 26 ) MATRIXX INITIATIVES, INC., ) 27 ) 28 Nominal Defendant. ) ) Case 2:09-cv-01899-SRB Document 1 Filed 09/11/09 Page 2 of 19 1 Plaintiff Timothy Hall (“Plaintiff”), by the undersigned attorneys, submits this 2 Verified Shareholder Derivative Complaint (the “Complaint”) against the defendants named 3 herein, and alleges upon personal knowledge with respect to himself, and upon information 4 and belief based upon, inter alia, a review of public filings, press releases and reports, and an 5 investigation undertaken by Plaintiff’s counsel, as to all other allegations herein, as follows: 6 NATURE OF THE ACTION 7 1.
    [Show full text]
  • Zicam® Cold Remedy Rapidmelts® Citrus
    ZICAM COLD REMEDY RAPIDMELTS CITRUS- zinc acetate anhydrous and zinc gluconate tablet Matrixx Initiatives, Inc. Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective. ---------- ® Zicam® Cold Remedy Rapidmelts Citrus Drug Facts Active ingredients (in each tablet) Zincum aceticum 2x Zincum gluconicum 1x Purpose Reduces duration and severity of the common cold Uses reduces duration of the common cold helps reduce severity of cold symptoms: sore throat stuffy nose sneezing coughing nasal congestion Zicam® Cold Remedy was formulated to shorten the duration of the common cold and was not formulated to be effective for flu or allergies. Warnings Ask a doctor before use if you have a sensitivity to zinc or are allergic to zinc Stop use and ask a doctor if symptoms persist or are accompanied by a fever or new symptoms occur If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Directions for best results, use at the first sign of a cold and continue to use until symptoms completely subside adults and children 12 years of age and older: take 1 tablet at the onset of symptoms dissolve entire tablet in mouth. Do not chew. Do not swallow whole. repeat every 2–3 hours, not to exceed 7 tablets in 24 hours. Take until symptoms are gone. to avoid minor stomach upset, do not take on an empty stomach do not eat or drink for 15 minutes after use.
    [Show full text]
  • Supreme Court of the United States ______
    No. 09-1156 IN THE Supreme Court of the United States __________ MATRIXX INITIATIVES, INC., ET AL., Petitioners, v. JAMES SIRACUSANO AND NECA-IBEW PENSION FUND, Respondents. __________ On Writ of Certiorari to the United States Court of Appeals for the Ninth Circuit __________ BRIEF FOR RESPONDENTS __________ DARREN J. ROBBINS DAVID C. FREDERICK ERIC ALAN ISAACSON Counsel of Record JOSEPH D. DALEY SCOTT H. ANGSTREICH SCOTT H. SAHAM GREGORY G. RAPAWY LUCAS F. OLTS EMILY T.P. ROSEN ROBBINS GELLER RUDMAN KELLOGG, HUBER, HANSEN, & DOWD LLP TODD, EVANS & FIGEL, 655 West Broadway P.L.L.C. Suite 1900 1615 M Street, N.W. San Diego, California 92101 Suite 400 (619) 231-1058 Washington, D.C. 20036 (202) 326-7900 SAMUEL H. RUDMAN ([email protected]) DAVID A. ROSENFELD ROBBINS GELLER RUDMAN & DOWD LLP 58 South Service Road Suite 200 Melville, New York 11747 (631) 367-7100 November 5, 2010 QUESTION PRESENTED Respondents are investors in petitioner Matrixx Initiatives, Inc. who claim that petitioners violated § 10(b) of the Securities Exchange Act of 1934 and Securities and Exchange Commission Rule 10b-5 by misrepresenting and by failing to disclose informa- tion about the safety of their drug products, includ- ing several independent reports by doctors linking intranasal applications of Matrixx’s Zicam products to persistent anosmia (loss of the sense of smell). Contrary to petitioners’ question presented, which asserts that this case concerns “a pharmaceutical company’s nondisclosure of adverse event reports even though the reports are not alleged to be statisti- cally significant,” this case does not involve “adverse event reports” required by the Food and Drug Administration.
    [Show full text]